Drug Profile
MegaCD40L
Latest Information Update: 23 Nov 2006
Price :
$50
*
At a glance
- Originator Apoxis
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Jul 2003 Preclinical trials in Cancer in Switzerland (unspecified route)